Description: The reinsurance market is experiencing unprecedented growth in both frequency and severity of catastrophic medical claims. Most experts identify specialty drugs, new gene therapies and high-intensity hospital in-patient stays as contributing factors. With Rx claims, high-cost drug protocols are creating chronic high-cost cases over multiple years. What can actuaries do to rapidly identify these cases? If identified, what techniques can be used to reduce or manage cost? Panel will include a nationally recognized consulting actuary, health plan executive and reinsurance executive.